Discovery of2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno[3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-KinaseInhibitors withIn VitroandIn VivoAntitumor Efficacy in Triple-Negative Breast Cancer

发表于 2026-9-29 14:25:33

期刊：Journal of Medicinal Chemistry

文献作者：Shabber Mohammed; Shabu Thakur; Diksha Manhas; Chilakala Nagarjuna Reddy; Abhisheik Eedara; Santosh K. Guru; Ajeet Singh; Mahir Bhardwaj; Vaishnavi Kambhampati; Ramajayan Pandian; Boobalan Gopu; Shashi Bhushan; Ram A. Vishwakarma; Sai Balaji Andugulapati; Shashank K. Singh; Utpal Nandi; Sandip B. Bharate

出版日期：2025-10-23

DOI号：10.1021/acs.jmedchem.5c01164

下载链接：https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5c01164

文献链接：https://doi.org/10.1021/acs.jmedchem.5c01164

当前文献来源于 American Chemical Society (ACS)。

备注信息：

发表于 2026-9-29 14:25:34

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ACS] Discovery of2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno[3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-KinaseInhibitors withIn VitroandIn VivoAntitumor Efficacy in Triple-Negative Breast Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ACS] Discovery of2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno[3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-KinaseInhibitors withIn VitroandIn VivoAntitumor Efficacy in Triple-Negative Breast Cancer 一键复制